Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells

  • Authors: Keiichi Kinoshita, Koji Nakagawa, Jun-Ichi Hamada, Yasuhiro Hida, Mitsuhiro Tada, Satoshi Kondo, Tetsuya Moriuchi
  • View Affiliations

  • Published online on: Friday, October 1, 2010
  • Pages: 869-877
  • DOI: 10.3892/ijo_00000738

Abstract

Platelet-derived growth factor (PDGF) is a significant mediator in the proliferation of cancer-associated stromal fibroblasts (CAFs). The inhibition of CAF proliferation by blocking PDGF signaling could lead to a development of novel cancer therapy. We analyzed whether inhibiting proliferation of lung CAFs by Imatinib mesylate, which has inhibitory activity on PDGF-receptor tyrosine kinase, could suppress the proliferative activity of lung cancer cells which coexisted in the tumor tissue. First, we established primary cultured fibroblasts from human lung cancer tissues. RT-PCR analysis showed that PDGF-receptors (PDGFRα and β) were more highly expressed in the fibroblasts, whereas PDGFs (PDGF-A, and -B) were more in lung cancer cell lines. Western blotting showed that Imatinib treatment inhibited phosphorylation of PDGFRβ, Akt, and Erk1/2 in the fibroblasts. The treatment also significantly inhibited the proliferative activity of the fibroblasts. The inhibitory effects were exerted more definitely in co-administering Imatinib and PDGF-BB, a dimer of the polypeptide chains of B, than in administering Imatinib alone. The conditioned media of the fibroblasts significantly increased the proliferative activity of human lung cancer cell line A549 compared to control culture medium. The proliferation-stimulating effect on A549 cells decreased significantly in the conditioned media of the primary cultured fibroblasts that had been treated with Imatinib. Our results suggest that Imatinib has antitumor activity which is exerted by reducing the proliferation-stimulating effect of CAFs on lung cancer cells, as well as inhibiting the proliferation of CAFs, by way of blocking PDGF signaling.
Journal Cover

October 2010
Volume 37 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

2013 Impact Factor: 2.773
Ranked #30/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kinoshita, K., Nakagawa, K., Hamada, J., Hida, Y., Tada, M., Kondo, S., & Moriuchi, T. (2010). Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. International Journal of Oncology, 37(4), 869-877.
MLA
Kinoshita, Nakagawa, Hamada, Hida, Tada, Kondo, and Tetsuya Moriuchi. "Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells." International Journal of Oncology International Journal of Oncology 37.4 (2010): 869-877.
Chicago
Kinoshita, Nakagawa, Hamada, Hida, Tada, Kondo, and Tetsuya Moriuchi. "Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells." International Journal of Oncology International Journal of Oncology 37 no. 4 (2010): 869-877.